| NCT04550325 | Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 | COMPLETED | PHASE1, PHASE2 | 2020-08-05 | 2020-11-26 | 2020-11-26 |
| NCT04204252 | Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" | RECRUITING | PHASE3 | 2019-11-25 | 2031-06 | 2028-12 |
| NCT02912845 | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies | COMPLETED | PHASE3 | 2016-08-01 | 2019-11-13 | 2019-11-13 |
| NCT02614872 | Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation | COMPLETED | PHASE2 | 2016-07-26 | 2019-05-07 | 2019-04-11 |
| NCT02001688 | Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" | COMPLETED | PHASE2 | 2014-04 | 2016-05 | 2016-02 |
| NCT02005848 | Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes | COMPLETED | PHASE2 | 2014-04 | 2017-02 | 2017-02 |
| NCT02040090 | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects | COMPLETED | PHASE2, PHASE3 | 2013-04 | 2014-08 | 2014-08 |
| NCT01304537 | Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus | COMPLETED | PHASE1, PHASE2 | 2011-06 | 2012-11 | 2012-11 |
| NCT01217671 | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema | COMPLETED | PHASE2, PHASE3 | 2009-12 | 2015-06 | 2014-11 |
| NCT00499837 | Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients | COMPLETED | PHASE2 | 2007-09 | 2008-07 | 2008-07 |
| NCT00460096 | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency | COMPLETED | PHASE2, PHASE3 | 2007-03 | 2007-09 | |